Preferred Label : Brepocitinib Tosylate;
NCIt definition : The tosylate form of brepocitinib, an orally available, selective inhibitor of non-receptor
tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1
(Janus kinase 1; JAK1), with potential immunomodulatory and anti-inflammatory activities.
Upon oral administration, brepocitinib selectively binds to and inhibits the activation
of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling.
This may reduce inflammatory responses and prevent inflammation-induced damage caused
by certain immunological diseases. TYK2 and JAK-1 are members of the Janus kinase
family of non-receptor tyrosine kinases and are involved in signaling pathways affecting
hematopoiesis, immunity and inflammation.;
UNII : C960DPP15O;
InChIKey : FAKGOYNHHHOTEN-VDTKTRGNSA-N;
CAS number : 2140301-96-6;
NCI Metathesaurus CUI : CL1405967;
Origin ID : C171779;
UMLS CUI : C5419294;
Semantic type(s)
- concept_is_in_subset
